An n-of-1 trial service in clinical practice: Testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder

Pediatrics

Volumn 117, Issue 6, 2006, Pages 2040-2046

  Nikles, C Jane ^a   Mitchell, Geoffrey K ^a   Del Mar, Chris B ^b   Clavarino, Alexandra ^a   McNairn, Norma ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b BOND UNIVERSITY   (Australia)

Author keywords

Attention deficit hyperactivity disorder; n of 1 trials

Indexed keywords

CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; METHYLPHENIDATE; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; GENERAL PRACTITIONER; HEALTH SERVICE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; OPTIMAL DRUG DOSE; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TELECOMMUNICATION; TREATMENT OUTCOME; FEMALE; MALE; METHODOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE;

EID: 33745319839     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-1328     Document Type: Article

References (34)

1. Barbaresi W, Katusic S, Colligan R, et al. How common is attention-deficit/hyperactivity disorder? Towards resolution of the controversy: results from a population-based study. Acta Paediatr Suppl. 2004;93(445):55-59
2. Graetz BW, Sawyer MG, Hazell PL, Arney F, Baghurst P. Validity of DSM-IV ADHD subtypes in a nationally representative sample of Australian children and adolescents. J Am Acad Child Adolesc Psychiatry. 2001;40:1410-1417
3. Topolski TD, Edwards TC, Patrick DL, Varley P, Way ME, Buesching DP. Quality of life of adolescent males with attention-deficit hyperactivity disorder. J Atten Disord. 2004;7:163-173
4. Mannuzza S, Klein R, Bessler A, Malloy P, Hynes M. Educational and occupational outcomes of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry. 1997;36:1222-1227
5. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch Pediatr Adolesc Med. 2002;156:504-511
6. Spencer T, Biererman J, Wilens T, Harding M, O'Donnell D, Griffen S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35:1591-1594
7. Sawyer MG, Rey JM, Graetz BW, Clark JJ, Baghurst PA. Use of medication by young people with attention-deficit/hyperactivity disorder. Med J Aust. 2002;177:21-25
8. Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36:141-155
9. Kent MA, Camfield CS, Camfield PR. Double-blind methylphenidate trials: practical, useful and endorsed by families. Arch Pediatr Adolesc Med. 1999;153:1292-1296
10. Queensland Department of Health. Prescribing Trends of Methylphenidate and Dexamphetamine. Brisbane, Queensland, Australia: Queensland Government; 1996
11. Berbatis CG, Sunderland VB, Bulsara M. Licit psychostimulant consumption in Australia, 1984-2000: international and jurisdictional comparison. Med J Aust. 2002;177:539-543
12. Sheather-Reid RB, Cohen ML. Efficacy of analgesics in chronic pain: a series of N-of-one studies. J Pain Symptom Manage. 1998;15:244-252
13. Mahon JM, Laupacis A, Donner A, Wood T. Randomised study of n-of-1 trials versus standard practice [published correction appears in BMJ. 1996;312:1392]. BMJ. 1996;312:1069-1074
14. Barbaresi WJ. Primary-care approach to the diagnosis and management of attention-deficit hyperactivity disorder. Mayo Clin Proc. 1996;71:463-471
15. McBride MC. An individual double-blind crossover trial for assessing dexamphetamine response in children with attention deficit disorder. J Pediatr. 1988;113:137-145
16. Varley CK, Trupin EW. Double-blind assessment of stimulant medication for attention deficit disorder: a model for clinical application. Am J Orthopsychiatry. 1983;53:542-547
17. Kamien M. The use of an N-of-1 randomised clinical trial in resolving therapeutic doubt: the case of a patient with an "attention disorder." Aust Fam Physician. 1998;27(suppl 2):S103-S105
18. Van Reekum R, Links PS. N-of-1 study: methylphenidate in a patient with borderline personality disorder and attention deficit hyperactivity disorder. Can J Psychiatry. 1994;39:186-187 1 9. Hale JB, Hoeppner JA, DeWitt MB, Coury DL, Ritacco DG, Trommer B. Evaluating medication response in ADHD: cognitive, behavioral, and single-subject methodology. J Learn Disabil. 1998;31:595-607
19. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The n-of-1 randomized controlled trial: clinical usefulness: our three-year experience. Ann Intern Med. 1990;112:293-299
20. Larson EB, Ellsworth AJ, Oas J. Randomized clinical trials in single patients during a 2-year period. JAMA. 1993;270:2708-2712
21. Shaw K, Mitchell G, Wagner I, Eastwood H. Attitudes and practices of general practitioners in the diagnosis and management of attention deficit hyperactivity disorder. J Paediatr Child Health. 2002;38:481-486
22. Duggan CM, Mitchell G, Nikles CJ, Glasziou PP, Del Mar CB, Clavarino A. Managing ADHD in general practice: N of 1 trials can help! Aust Fam Physician. 2000;29:1205-1209
23. Nikles J, Glasziou P, Del Mar C, Duggan C, Mitchell G. N of 1 trials: practical tools for medication management. Aust Fam Physician. 2000;29:1108-1112
24. Nikles CJ, Yelland M, Glasziou PP, Mar CD. Do individualized medication effectiveness tests (n-of-1 trials) change clinical decisions about which drugs to use for osteoarthritis and chronic pain? Am J Ther. 2005;12:92-97
25. Coxeter P, Schluter P, Eastwood H, Nikles J, Glasziou P. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement Ther Med. 2003;11:215-222
26. Conners CK, Sitarenios G, Parker JDA, Epstein JN. Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26:279-291
27. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998
28. Nikles CJ, Clavarino AM, Del Mar CB. Using n-of-1 trials as a clinical tool to improve prescribing. Br J Gen Pract. 2005;55:175-180
29. Askew DA. A Study of Research Adequacy in Australian General Practice [PhD thesis]. Herston, Queensland, Australia: School of Population Health, The University of Queensland; 2005
30. Varley CK, Trupin EW. Double-blind administration of methylphenidate to mentally retarded children with attention deficit disorder; a preliminary study. Am J Ment Defic. 1982;86:560-566
31. March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P. n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ. 1994;309:1041-1045; discussion 1045-1046
32. Thomson JB, Varley CK. Prediction of stimulant response in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 1998;8:125-132
33. Arnold LE, Elliot M, Sachs L, et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol. 2003;71:713-727
34. Kent L. Recent advances in the genetics of attention deficit hyperactivity disorder. Curr Psychiatry Rep. 2004;6:143-148